Trials show small signals on lab markers, such as a few more mature oocytes or better embryo grades, but a live-birth benefit has not been established
Below: injectable, IV, and buccal protocols with documented dose ranges, delivery-route trade-offs, and reconstitution math for the full mechanism and age-decline research, see the glutathione peptide page
In contrast, tirzepatide, a dual GIPR/GLP-1R agonist, has been approved for the treatment of T2DM and additionally produces significant weight loss (Le Roux et al., 2023)
Combined support strategies include: Integrated treatment planning Multi-specialist coordination Regular progress assessment Flexible intervention methods Family education programs School-home communication systems Why Understanding the Difference Matters Tailoring Interventions Understanding differences between conditions leads to more effective support